Bosentan - Generic Drug Details

What are the generic drug sources for bosentan and what is the scope of freedom to operate?

Bosentan is the generic ingredient in two branded drugs marketed by Natco Pharma Ltd, Actelion, Alembic, Alvogen Pine Brook, Amneal Pharms Co, Chartwell Molecular, Hikma, Mylan, Ph Health, Sun Pharm, Watson Labs Inc, and Zydus Pharms, and is included in fourteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bosentan has twenty-eight patent family members in twenty-three countries.

There are nineteen drug master file entries for bosentan. Six suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for bosentan

International Patents:	28
US Patents:	2
Tradenames:	2
Applicants:	12
NDAs:	14
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	136
Patent Applications:	6,989
Drug Prices:	Drug price trends for bosentan
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bosentan
What excipients (inactive ingredients) are in bosentan?	bosentan excipients list
DailyMed Link:	bosentan at DailyMed

See drug prices for bosentan

Recent Clinical Trials for bosentan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
Boehringer Ingelheim	PHASE1
University of Edinburgh	PHASE2

See all bosentan clinical trials

Generic filers with tentative approvals for BOSENTAN

Applicant	Application No.	Strength	Dosage Form
		125MG	TABLET;ORAL
		62.5MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bosentan

Drug Class	Endothelin Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A Inducers Endothelin Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for bosentan

C02KX	Antihypertensives for pulmonary arterial hypertension
C02K	OTHER ANTIHYPERTENSIVES
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

Paragraph IV (Patent) Challenges for BOSENTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRACLEER	for Oral Suspension	bosentan	32 mg	209279	1	2019-02-08

US Patents and Regulatory Information for bosentan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	BOSENTAN	bosentan	TABLET;ORAL	209324-002	Apr 26, 2019	AB	RX	No	No
Natco Pharma Ltd	BOSENTAN	bosentan	TABLET;ORAL	206987-002	Apr 26, 2019		DISCN	No	No
Amneal Pharms Co	BOSENTAN	bosentan	TABLET;ORAL	209742-001	Apr 26, 2019		DISCN	No	No
Natco Pharma Ltd	BOSENTAN	bosentan	TABLET, FOR SUSPENSION;ORAL	213154-001	Feb 5, 2025	AB	RX	No	No
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-002	Nov 20, 2001	AB	RX	Yes	Yes

Expired US Patents for bosentan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-001	Nov 20, 2001
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-002	Nov 20, 2001

EU/EMA Drug Approvals for bosentan

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Tracleer	bosentan	EMEA/H/C/000401Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,	Authorised	no	no	no	2002-05-14

International Patents for bosentan

Country	Patent Number	Title	Estimated Expiration
South Korea	20080014002	DISPERSIBLE TABLET
Hong Kong	1120212	DISPERSIBLE BOSERTAN TABLET
World Intellectual Property Organization (WIPO)	2006123285
Austria	E451914
Poland	1883397

Supplementary Protection Certificates for bosentan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0526708	SPC/GB02/030	United Kingdom		PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
0526708	02C0042	France		PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
0526708	0290017-3	Sweden		PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228

BOSENTAN: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

BOSENTAN, a dual endothelin receptor antagonist, is a critical therapeutic agent for pulmonary arterial hypertension (PAH). Its market performance is shaped by patent expirations, generic competition, evolving treatment guidelines, and the introduction of newer therapies. The drug's financial trajectory reflects these market forces, with significant revenue generation during its patent-protected period and subsequent revenue decline post-exclusivity.

What is the current market status of BOSENTAN?

The market status of BOSENTAN is characterized by its transition from a branded, patent-protected product to a market with established generic competition. Actelion Pharmaceuticals (now part of Johnson & Johnson) originally developed and marketed BOSENTAN under the brand name Tracleer.

• Branded vs. Generic Landscape: The original patent for BOSENTAN (and its formulation) expired in many key markets, opening the door for generic manufacturers. This has led to a significant increase in the number of generic BOSENTAN products available.
• Pricing Pressures: The entry of generics has resulted in substantial price reductions for BOSENTAN. Branded Tracleer experienced significant revenue declines following generic entry due to direct competition on price and the availability of multiple generic alternatives.
• Market Share Erosion: While BOSENTAN remains a recognized treatment option for PAH, its overall market share has diminished as newer, potentially more effective, or more convenient treatment options have emerged. However, its established efficacy and familiarity ensure continued use, particularly in specific patient populations or regions where cost is a primary consideration.
• Geographic Variations: The pace of generic entry and the resulting market dynamics vary by region, influenced by patent expiry dates, regulatory approval processes, and healthcare reimbursement policies in different countries.

What are the key intellectual property (IP) milestones for BOSENTAN?

The intellectual property landscape for BOSENTAN has been crucial in defining its market exclusivity and subsequent revenue streams. The primary IP assets were patents covering the compound itself, its formulations, and methods of use.

• Core Compound Patents: The initial patents covering the BOSENTAN molecule provided the foundational exclusivity. For instance, U.S. Patent No. 5,290,775, filed in 1992 and expiring in 2012, was a key patent for the compound. [1]
• Formulation and Method of Use Patents: Additional patents were granted for specific formulations (e.g., tablet composition) and methods of treating PAH, extending market exclusivity beyond the core compound patent expiry. These secondary patents often became targets for Paragraph IV patent certifications by generic companies seeking to challenge their validity or non-infringement.
• Patent Expiry Dates and Generic Entry: The expiry of key patents was the trigger for widespread generic competition.
  • In the United States, the last-standing patents for Tracleer expired around 2014-2015, following significant patent litigation. [2]
  • In Europe, patent expiries also led to the introduction of generics, with market exclusivity generally ending in the early to mid-2010s.
• Patent Litigation: The patent life of Tracleer was marked by extensive litigation. Actelion defended its patents against challenges from generic manufacturers. These legal battles often determined the precise timing of generic market entry and the extent of post-patent erosion.

What is the historical financial performance of BOSENTAN?

The financial performance of BOSENTAN, primarily as Tracleer, demonstrates a classic lifecycle trajectory of a successful branded pharmaceutical.

• Peak Sales: Tracleer achieved significant peak annual sales. In 2011, prior to widespread generic entry, Actelion reported net sales of approximately CHF 2.1 billion (USD 2.4 billion at the time's exchange rates) for Tracleer. [3]
• Revenue Generation: The drug was a major revenue driver for Actelion for over a decade, funding its R&D efforts and acquisitions. Its success was attributed to being one of the first oral therapies approved for PAH, a serious and previously underserved condition.
• Post-Generic Impact: Following generic entry, Tracleer's sales experienced a sharp decline.
  • By 2016, net sales of Tracleer had fallen to CHF 509 million, a substantial decrease from its peak. [4]
  • Further declines continued, with sales in the low hundreds of millions of Swiss Francs in subsequent years.
• Generic Market Sales: While specific figures for the total global generic BOSENTAN market are fragmented across numerous manufacturers, the aggregate market size for generic BOSENTAN is considerably smaller than Tracleer's peak, reflecting the impact of price erosion.

Year	Tracleer Net Sales (CHF Million)	Approximate USD Equivalent (Billion)
2011	2,100	2.4
2012	2,110	2.3
2013	1,810	2.0
2014	1,160	1.3
2015	741	0.8
2016	509	0.5

Note: Exchange rates for USD equivalents are approximate and based on the average annual exchange rate for the respective year.

How do current and future treatment guidelines impact BOSENTAN?

Treatment guidelines for Pulmonary Arterial Hypertension (PAH) significantly influence the positioning and utilization of BOSENTAN. These guidelines are periodically updated based on new clinical trial data and emerging therapeutic options.

• Evolving Treatment Paradigms: The PAH treatment landscape has evolved considerably since BOSENTAN's initial approval. Guidelines now often recommend a multi-drug approach, frequently initiating therapy with combination treatments.
• BOSENTAN's Role: BOSENTAN is still recognized in guidelines as an effective monotherapy or as part of combination therapy for certain PAH patient groups, particularly those with WHO Functional Class II or III PAH.
  • The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines have historically included BOSENTAN. [5]
  • Current recommendations tend to favor newer agents or specific combination strategies upfront, potentially limiting BOSENTAN's role as a first-line monotherapy in many regions.
• Comparison with Newer Agents: Newer PAH therapies, including prostacyclin pathway agents (oral and inhaled), selective endothelin receptor antagonists (e.g., macitentan, ambrisentan), and phosphodiesterase-5 (PDE5) inhibitors, have been introduced. Some of these newer agents have demonstrated improved outcomes in head-to-head comparisons or in specific patient subgroups, influencing prescriber preference and guideline recommendations. For example, macitentan, also developed by Actelion, has shown benefits in reducing morbidity and mortality. [6]
• Cost-Effectiveness: As a generic drug, BOSENTAN offers a more cost-effective treatment option compared to many newer branded therapies. This makes it a viable choice in healthcare systems with budget constraints or for patients with limited insurance coverage.
• Future Outlook: The future role of BOSENTAN in treatment guidelines will likely depend on its continued demonstration of efficacy in real-world studies, its cost-effectiveness, and the specific outcomes achieved by newer agents in comparative studies. It is expected to remain an important treatment option, particularly as a component of combination therapy or as a cost-effective alternative in specific settings.

What are the key competitive forces in the PAH market affecting BOSENTAN?

The competitive landscape for BOSENTAN is multifaceted, encompassing both direct generic competitors and a broader array of novel therapeutic agents for PAH.

• Generic Competition: The most direct competitive pressure comes from multiple generic manufacturers producing BOSENTAN. This has led to commoditization and significant price erosion, as detailed previously.
• Other Endothelin Receptor Antagonists (ERAs):
  • Ambrisentan: Marketed as Letairis (Gilead Sciences/Myogen), ambrisentan is another ERA that competes directly with BOSENTAN. It offers a different safety profile and dosing regimen.
  • Macitentan: Marketed as Opsumit (Janssen/Actelion), macitentan is a newer ERA that has demonstrated superior efficacy in reducing morbidity and mortality endpoints compared to some older ERAs in clinical trials, positioning it as a preferred option in advanced treatment guidelines. [6]
• Prostacyclin Pathway Agents: This class of drugs, including intravenous/subcutaneous epoprostenol, treprostinil, and iloprost, as well as oral and inhaled forms of selexipag (Uptravi), represent another significant competitive force. These agents are often used in more severe PAH cases.
• Phosphodiesterase-5 (PDE5) Inhibitors: Sildenafil (Revatio/various generics) and tadalafil (Adcirca/various generics) are approved for PAH and are widely used, often in combination with other therapies. They offer a different mechanism of action and contribute to the crowded treatment landscape.
• Combination Therapies: The increasing adoption of upfront combination therapy in PAH guidelines means that BOSENTAN competes not just as a monotherapy but also against specific synergistic combinations of drugs from different classes. This often favors newer agents with established combination trial data.
• Emerging Therapies: Ongoing research and development in PAH continue to introduce new molecular targets and therapeutic strategies, potentially further altering the competitive dynamics.

What is the future financial outlook for BOSENTAN?

The future financial outlook for BOSENTAN is characterized by its established generic status and its continued, albeit reduced, market presence.

• Sustained Generic Sales: BOSENTAN will continue to generate revenue through generic sales. The volume of prescriptions is likely to remain stable or decline gradually, depending on the efficacy and adoption rates of newer therapies.
• Price Sensitivity: The market for generic BOSENTAN is highly price-sensitive. Competition among generic manufacturers will keep prices low, limiting the overall revenue potential for any single generic producer.
• Market Penetration in Emerging Markets: There may be opportunities for increased penetration of generic BOSENTAN in emerging markets where cost-effectiveness is a paramount consideration and access to newer, more expensive therapies is limited.
• Role in Combination Therapy: BOSENTAN is likely to retain a role in combination therapy, particularly where cost is a significant factor. This could provide a baseline level of demand.
• Limited Growth Potential: Significant growth in BOSENTAN sales is highly unlikely. The market has matured, and the drug's primary revenue-generating period as a branded product is over. Future revenue will be fragmented among numerous generic companies.
• R&D Focus Shift: Pharmaceutical companies that previously relied on BOSENTAN for revenue have shifted their R&D focus to newer, more innovative compounds with potentially higher revenue ceilings and longer exclusivity periods.

Key Takeaways

BOSENTAN's market trajectory exemplifies the typical lifecycle of a highly successful pharmaceutical product. Its initial patent-protected period was marked by significant revenue generation, establishing it as a cornerstone therapy for pulmonary arterial hypertension. The subsequent expiry of its key patents led to the inevitable entry of generic competition, resulting in substantial price erosion and a dramatic decline in branded sales. While BOSENTAN remains a clinically relevant and cost-effective treatment option, particularly in combination therapies and in cost-sensitive markets, its future financial outlook is one of stable, low-margin generic revenue rather than growth. The competitive landscape is robust, with newer agents and evolving treatment guidelines continuing to shape the PAH market, influencing BOSENTAN's relative positioning.

Frequently Asked Questions

1. What is the primary mechanism of action for BOSENTAN? BOSENTAN is a dual endothelin receptor antagonist (ERA). It blocks the action of endothelin-1 (ET-1) by binding to both ETᴀ and ETʙ receptors. ET-1 is a potent vasoconstrictor, and its overactivity contributes to the increased pulmonary vascular resistance seen in PAH. By blocking ET-1, BOSENTAN causes vasodilation, which reduces pulmonary arterial pressure and improves symptoms.

2. What are the main adverse effects associated with BOSENTAN therapy? Common adverse effects of BOSENTAN include peripheral edema, headache, and hepatic enzyme elevations. The monitoring of liver function is a critical aspect of BOSENTAN therapy due to the risk of hepatotoxicity. Other potential side effects include anemia and decreased hemoglobin levels.

3. Is BOSENTAN still considered a first-line treatment for PAH? While BOSENTAN is still recognized as an effective treatment for PAH, particularly for patients with WHO Functional Class II or III disease, it is not universally considered the first-line monotherapy in current treatment guidelines. Newer agents, or upfront combination therapy, are often preferred, especially in patients with higher risk profiles or specific comorbidities, due to improved efficacy data in reducing morbidity and mortality. However, its cost-effectiveness as a generic may lead to its use as a first-line option in certain healthcare systems or patient populations.

4. Which companies are major generic manufacturers of BOSENTAN? Numerous generic pharmaceutical companies manufacture and market BOSENTAN. These include, but are not limited to, companies like Teva Pharmaceuticals, Mylan N.V. (now Viatris), Accord Healthcare, and numerous other regional and global generic producers. The specific market share of each generic manufacturer can vary significantly by country.

5. Beyond PAH, are there other approved uses for BOSENTAN? BOSENTAN is primarily approved for the treatment of pulmonary arterial hypertension (PAH). While research may explore its potential in other conditions involving vasoconstriction or endothelial dysfunction, its established and marketed indication is limited to PAH.

Citations

[1] U.S. Patent No. 5,290,775. (1992). Therapeutically effective compositions containing endothelin antagonists. [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] [3] Actelion Ltd. (2012). Annual Report 2011. [4] Actelion Ltd. (2017). Annual Report 2016. [5] Galiè, N., Humbert, M., Badimon, L., et al. (2015). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). European Heart Journal, 37(1), 67–119. [6] Pulido, T., Adir, Y., Tan, R. T., et al. (2013). Macitentan for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 369(9), 809–818.